Author

C. L. Bevan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Neodo· 1 shared A. T. Bakker· 1 shared C. Xu· 1 shared D. A. Leach· 1 shared E. A. Mathe· 1 shared E. D. Williams· 1 shared E. De Vita· 1 shared E. Engelsberger· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. Neodo

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

The antiviral potential of the antiandrogen enzalutamide and the viral-androgen interplay in seasonal coronaviruses

O. D. Ogunjinmi, T. Abdullahi, R.-A. Somji, C. L. Bevan, W. S. Barclay, N. J. Temperton, G. N. Brooke, E. S. Giotis

This study investigates enzalutamide's antiviral effects against seasonal coronaviruses and identifies differences in viral-androgen signaling interactions between HCoV-229E and HCoV-OC43.

bioRxiv · Nov 25, 2023 · PreprintMicrobiology

Detection of YAP1 and AR-V7 mRNA for Prostate Cancer prognosis using an ISFET Lab-On-Chip platform

J. J. Broomfield, M. Kalofonou, T. Pataillot-Meakin, S. M. Powell, N. Moser, C. L. Bevan, P. Georgiou

This paper develops a Lab-on-Chip platform using RT-LAMP and ISFET sensors to detect AR-V7 and YAP1 mRNA in prostate cancer for prognosis and drug resistance monitoring.

bioRxiv · Aug 4, 2022Bioengineering

A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer

S. Lovell, L. Zhang, T. Kryza, A. Neodo, N. Bock, E. D. Williams, E. Engelsberger, C. Xu, A. T. Bakker, E. De Vita, M. Maneiro, R. J. Tanaka, C. L. Bevan, J. A. Clements, E. W. Tate

The paper develops activity-based probes to analyze KLK activome dynamics in prostate cancer, revealing KLK14's role in migration and secretion into the bone microenvironment.

bioRxiv · Apr 15, 2021Biochemistry

Genome-wide analyses of transcription factors and co-regulators across seven cohorts identified reduced PPARGC1A expression as a driver of prostate cancer progression

M. Siddappa, S. A. Wani, M. D. Long, D. A. Leach, E. A. Mathe, C. L. Bevan, M. J. Campbell

bioRxiv · May 12, 2020 · PreprintCancer Biology